Find therapies in clinical trials near you – page 5

Study of drug combination with gemcitabine, cisplatin, carboplatin and avelumab in patients with advanced urothelial cancer to evaluate response to platinum-based chemotherapy

Study of drug combination with gemcitabine, cisplatin, carboplatin and avelumab in patients with advanced urothelial cancer to evaluate response to platinum-based chemotherapy

Study of MK-7684A and Pembrolizumab for Patients with Advanced Solid Tumors

Study of MK-7684A and Pembrolizumab for Patients with Advanced Solid Tumors

Study Comparing Epcoritamab with Chemotherapy for Patients with Relapsed or Refractory B-cell Lymphoma

Study on Berzosertib and Gemcitabine for Adults with Advanced or Metastatic Soft-Tissue Leiomyosarcomas

Study on Berzosertib and Gemcitabine for Adults with Advanced or Metastatic Soft-Tissue Leiomyosarcomas

Study on the Effectiveness and Safety of Immunotherapy with Atezolizumab, Bevacizumab, and Tiragolumab for Patients with Metastatic Pancreatic Cancer

Study on the Effectiveness and Safety of Immunotherapy with Atezolizumab, Bevacizumab, and Tiragolumab for Patients with Metastatic Pancreatic Cancer

Study on TAR-200 and Cetrelimab for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Not Received BCG Treatment

Study on TAR-200 and Cetrelimab for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Not Received BCG Treatment

Study of Nadunolimab with Gemcitabine and Carboplatin for Patients with Advanced Triple Negative Breast Cancer

Study of Nadunolimab with Gemcitabine and Carboplatin for Patients with Advanced Triple Negative Breast Cancer

Study on Atezolizumab for Patients with Non-Small Cell Lung Cancer After Chemotherapy

Study on Atezolizumab for Patients with Non-Small Cell Lung Cancer After Chemotherapy

Study on TAR-200 and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Ineligible for or Refusing Platinum-Based Chemotherapy

Study on TAR-200 and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Ineligible for or Refusing Platinum-Based Chemotherapy

Study Comparing TAR-200 and Chemotherapy for Patients with High-Risk Non-Muscle-Invasive Bladder Cancer After BCG Treatment

Study Comparing TAR-200 and Chemotherapy for Patients with High-Risk Non-Muscle-Invasive Bladder Cancer After BCG Treatment

Study on TAR-200 and Cetrelimab for High-Risk Bladder Cancer Patients Not Responding to BCG and Unable or Unwilling to Have Surgery

Study on TAR-200 and Cetrelimab for High-Risk Bladder Cancer Patients Not Responding to BCG and Unable or Unwilling to Have Surgery

Study of Alectinib and Platinum-Based Chemotherapy for Patients with Resected Stage Ib to IIIa ALK-Positive Non-Small Cell Lung Cancer

Study of Alectinib and Platinum-Based Chemotherapy for Patients with Resected Stage Ib to IIIa ALK-Positive Non-Small Cell Lung Cancer